Abstract | BACKGROUND: OBJECTIVE: To determine whether absolute insulin deficiency or insulin resistance with relative insulin deficiency and an elevated body mass index (BMI) contribute to HIV PI-associated diabetes. DESIGN: Cross-sectional evaluation. PATIENTS: 8 healthy seronegative men, 10 nondiabetic HIV-positive patients naive to PI, 15 nondiabetic HIV-positive patients receiving PI (BMI = 26 kg/m2), 6 nondiabetic HIV-positive patients receiving PI (BMI = 31 kg/m2), and 8 HIV-positive patients with diabetes receiving PI (BMI = 34 kg/m2). All patients on PI received indinavir. MEASUREMENTS: Fasting concentrations of glucoregulatory hormones. Direct effects of indinavir (20 microM) on rat pancreatic beta-cell function in vitro. RESULTS: CONCLUSIONS:
|
Authors | K E Yarasheski, P Tebas, C Sigmund, S Dagogo-Jack, A Bohrer, J Turk, P A Halban, P E Cryer, W G Powderly |
Journal | Journal of acquired immune deficiency syndromes (1999)
(J Acquir Immune Defic Syndr)
Vol. 21
Issue 3
Pg. 209-16
(Jul 01 1999)
ISSN: 1525-4135 [Print] United States |
PMID | 10421244
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-HIV Agents
- C-Peptide
- HIV Protease Inhibitors
- Insulin
- Indinavir
- Glucagon
- Proinsulin
- Phospholipases A
|
Topics |
- Adult
- Animals
- Anti-HIV Agents
(adverse effects, therapeutic use)
- C-Peptide
(metabolism)
- Cells, Cultured
- Cross-Sectional Studies
- Diabetes Mellitus, Type 1
(complications)
- Glucagon
(metabolism)
- HIV Infections
(complications, drug therapy)
- HIV Protease Inhibitors
(adverse effects, therapeutic use)
- Humans
- Indinavir
(adverse effects, therapeutic use)
- Insulin
(metabolism)
- Insulin Resistance
- Islets of Langerhans
(metabolism)
- Male
- Phospholipases A
(metabolism)
- Proinsulin
(metabolism)
- Rats
- Rats, Sprague-Dawley
|